Signal Transduction Pathways in Gynecologic Malignancies

Dear Colleagues,

Gynecologic cancers are malignancies originating in the female reproductive organs, including the cervix, ovaries, uterus, fallopian tubes, vagina, and vulva.

The American Cancer Society estimates that 98,280 new cases of gynecologic cancers will be diagnosed in the US in 2015. Furthermore, 30,440 women with gynecologic cancers will die of their disease. Ovarian carcinoma is the leading cause of death from gynecologic malignancies and will account for 14,180 deaths in 2015.

In recent years, extensive progress has been made  in developing both treatments of early stage gynecologic cancers and preventive measures. However, in many cases, the lack of reliable criteria for early diagnosis hampers tumor detection at early stages, when these cancers can be treated with  existing approaches. In most cases, the cause of death from gynecologic cancers is metastatic disease that cannot be cured by the standard of care approaches.This Special Issue focuses on “signal transduction pathways in gynecologic malignancies”. We aim to provide an overview of the present state of knowledge concerning key molecular pathways that drive metastatic progression in these diseases.

We would like to invite submissions of research and review manuscripts that cover any aspects of the signal transduction pathways underlying the progression of gynecologic malignancies. Areas of particular interest include, but are not limited to: signal transduction pathways in ovarian, cervical, endometrial, and other gynecologic malignancies, oncogenes and metastasis suppressors, mechanisms of chemoresistance, and novel therapies for treating gynecologic malignancies.

We look forward to reading your contributions,

Dr. Maria Barbolina
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.